anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses a  18  An F-labeled radioactive tracer and a preparation method thereof belong to the field of molecular imaging probes. The structure of the radioactive tracer is shown in a formula I. The invention firstly proposes direct marking on trifluoromethylated 1,2, 3-triazole compounds  18  F, successfully constructed 5-CF  2   18  F-1,2, 3-triazole compounds. The 5-CF provided by the invention  3  The (E) -1,2, 3-triazole compound can be used for preparing medicaments for preventing and/or treating various cancers such as ovarian cancer, prostatic cancer, cervical cancer and the like, and the 5-CF provided by the invention  2   18  The F-1,2, 3-triazole compound can be used as a radioactive tracer for observing the metabolism condition of a drug molecule in a living body. Construction of 5-CF according to the invention  2   18  The method for preparing the F-1,2, 3-triazole compound has the advantages of easily obtained raw materials, low cost, simple and convenient operation, safety, controllability and high reflection yield of the obtained product. The method of the invention is realized in the last step  18  F marks, reduces decay time and is beneficial to the in-vivo application of the product.
Participants receive BL-M17D1 as intravenous infusion for the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
The invention discloses a totarol antibacterial nano hydrogel with a whey protein as a matrix and a preparation method thereof, and belongs to the bacteriostatic gel biological technical field. Preparation raw materials comprise a whey protein gel, totarol and absolute ethyl alcohol. The preparation method adopts a sol-gel technique and comprises the steps of whey protein gel preparation, totarol embedding, ultrasonic treatment and standing and sterilization. According to the antibacterial nano hydrogel formula, a novel food-borne bacteriostatic agent is achieved. At the same time, the antibacterial nano hydrogel has the characteristics and advantages of the whey protein and the totarol. A whey protein polymer plays dispersion stabilizer, gel matrix and multiple roles in the antibacterial nano hydrogel system, no any crosslinking agents and initiators are added, toxic effects on a human body cannot be produced, and the use is safer and more effective; the preparation method has the advantages of simple equipment and technological process for producing the antibacterial nano hydrogel, mild conditions, low cost and easy popularization, and is suitable for industrialized production.
The experimenter holds both knees with one arm while placing their opposite hand on the participant's lumbar spine. The experimenter performs 1 min of ﬂexion and extension PROM without reaching physiological end range in either direction of movement. This is repeated with the subject in left sidelying.
The present disclosure provides methods for protecting and expanding hematopoietic cells. The present disclosure also provides methods of increasing the efficacy of hematopoietic cells. Aspects of the methods include contacting a starting population of hematopoietic cells with a therapeutically effective amount of at least one ALDH2 agonist. Aspects include in vivo, in vitro, and ex vivo methods of protecting, expanding, and increasing the efficacy of hematopoietic cells. Aspects of the methods include treating an individual who is receiving chemotherapy or radiation therapy for cancer, has been exposed to a destructive toxin, has a genetic disease that results in HSC damage, bone marrow failure, autoimmune disease, or the development of hematological malignancies. Aspects of the methods also include treating a healthy individual as a donor of stem cell transplantation.
Eight non-intubated Covid-19 patients confirmed by real-time viral RNA PCR tests were included. Four patients had been administered two doses of 200 mL convalescent plasma (CP) and another four patients had been administered one dose of CP with an antibody titer of 1:320. This study has three goals included to detect the improvement of patient clinical and laboratory conditions, safety of CPT, and conversion from positive to negative results after CPT administration. Convalescent plasma applied within two weeks (13 days) from onset of illness and within a week (6.5 days) from the first day of hospital admission for all patients. Improvements in clinical symptoms, laboratory parameters, thorax photo, negative conversion of PCR, and decreased oxygen supplementation occurred within a week after CPT. Patients with two doses of CP tended to have faster recovery than those with one dose of CP. No severe adverse effects were observed in any patient. This is the first case series in Indonesia showing CPT is safe and well tolerated, and early CPT before the patient is intubated could potentially prevent disease progression, increase the recovery rate, and shorten the inpatient days.
CASE: A 42-year-old woman presented with left-sided axial neck pain with radiation behind left ear of 3 months unresponsive to conservative treatment. As clinical examination revealed tenderness anterior to the mastoid process, she was referred to an otolaryngologist. Computed tomography showed an elongated left styloid process. Diagnostic local anesthetic infiltration provided complete pain relief confirming the diagnosis of Eagle syndrome (ES) after which a transoral excision of the left styloid process was performed. She was asymptomatic till the final follow-up of 15 months.
CONCLUSION: ES should be considered in differential diagnosis of axial neck pain radiating to ear, and excision of the styloid process in resistant cases provides complete pain relief.
Pathogens typically responsible for hospital-acquired infections (HAIs) constitute a major threat to healthcare systems worldwide. They spread via hospital (or hospital-community) networks by readmissions or patient transfers. Therefore, knowledge of these networks is essential to develop and test strategies to mitigate and control the HAI spread. Until now, no methods for comparing healthcare networks across different systems were proposed. Based on healthcare insurance data from four German federal states (Bavaria, Lower Saxony, Saxony and Thuringia), we constructed hospital networks and compared them in a systematic approach regarding population, hospital characteristics, and patient transfer patterns. Direct patient transfers between hospitals had only a limited impact on HAI spread. Whereas, with low colonization clearance rates, readmissions to the same hospitals posed the biggest transmission risk of all inter-hospital transfers. We then generated hospital-community networks, in which patients either stay in communities or in hospitals. We found that network characteristics affect the final prevalence and the time to reach it. However, depending on the characteristics of the pathogen (colonization clearance rate and transmission rate or even the relationship between transmission rate in hospitals and in the community), the studied networks performed differently. The differences were not large, but justify further studies.
Seizures occur in up to 59% of boys with creatine transporter deficiency (CTD). While seizure phenotypes have been previously described, electroencephalogram (EEG) findings have only been reported in several case reports. In this prospective observational study, we report seizure characteristics and EEG findings in combination with neurobehavioral and SLC6A8 pathogenic variants in twenty males with CTD. Eighteen study participants (SP) underwent video-EEG, and seven had follow-up EEG recordings. Seizures typically occurred by age of 2 years. Thirteen (65%) had non-febrile seizures, requiring anti-seizure medications in nine. Four had febrile seizures. Seizures were bilateral tonic-clonic in 7 SP and focal impaired awareness in 5 SP; often responding to 1 to 2 antiseizure medications. EEG showed slowing in 5 SP, beta activity in 6 SP, and focal/multifocal, and/or generalized epileptiform activity in 9 SP. Follow-up EEGs in 7 SP showed emergence of epileptiform activity in 1 SP, and increased activity in 2 SP. In conclusion, seizures were frequent in our cohort but tended to respond to antiseizure medications. Longitudinal follow up provided further insight into emergence of seizures and EEG abnormalities soliciting future studies with long term follow up. Biomarkers of epileptogenicity in CTD are needed to predict seizures in this population.
Exercise will be performed on a treadmill, with the initial intensity of 60% of the maximum predicted heart rate for patient´s age (Tanaka et al, 2001) reaching a maximal of 80% during the training. The intensity values will be calculated using Karvonen's formule (1957).Aerobic training sessions that will consist in 40 minutes divided in 5 minutes of warm-up, 35 minutes of aerobic training and 5 minutes of cool down. Exercise intensity will be increased if the patient do not present any increase in asthma symptoms during the exercise for 2 consecutive training days. The program will be performed twice a week, for 3 months.
On Days 7 and 14, a single blood sample will be collected immediately (e.g. within 30 minutes) prior to administering the next ITZ dose. After initiating an EFV based regimen, a single blood sample will be collected immediately (e.g. within 30 minutes) prior to administering the next ITZ dose on Days 7 and 14.
The patient will wear the BHD 5 cm above the needle insertion site for the duration of the procedure. The BHD will deliver constant low-frequency vibration (CF).
A course of therapy will include 7 weeks of treatment. SGT-53, at 3.6 mg DNA/infusion, will be administered bi-weekly on days 1 and 5 in weeks 1-3, weekly on day 3 in week 4, and weekly on day 1 in weeks 5-7. Patients who are responding to treatment may receive two additional courses (7 weeks) of SGT-53/gemcitabine/nab-paclitaxel therapy at investigator discretion. If still responding to treatment, they may continue on SGT-53/gemcitabine/nab-paclitaxel at investigator discretion with the approval of the sponsor.
PURPOSE: To make the in vitro growth of a fetal bovine from fertilization to transplantable blastocysts effective by culturing the animal epithelial cells in a medium until the medium can maintain the health and vitality of the fetal bovine through 8 to 16 cell stages. CONSTITUTION: The fresh epithelial cells obtd. from a donor subject are added to the medium. The medium alone is insufficient for culturing the fetal bovine after passing the 8 to 16 cell stages. The epithelial cells are cultured in the medium until the medium can maintain the health and vitality of the fetal bovine through the 8 to 16 cell stages, by which the in vitro fetal bovine culture system is prepd. The epithelial cells are adequately removed from the medium after the medium is made adjustable by the presence of the epithelial cells. The culture of the epithelial cells simultaneously with the fetal bovine is adequate in the culture stage.
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of TEGSEDI cannot be directly compared to rates in clinical trials of other drugs and may not reflect the rates observed in practice.

A total of 112 adult patients with polyneuropathy caused by hereditary transthyretin-mediated amyloidosis (hATTR) received TEGSEDI in Study 1 and 60 patients received placebo. The, mean age of the study patients was 59 years (27 to 78 years of age). Of the TEGSEDI-treated patients, 69% were male and 94% were Caucasian, with a mean exposure of 385 days, and median exposure of 449 days. Baseline disease characteristics were largely similar in TEGSEDI-treated patients and patients in the placebo control group. Sixty-seven percent of patients were in Stage 1 of the disease at baseline, and 33% in Stage 2. Fifty-two percent of patients had Val30Met mutations in the TTR gene, with the remaining 48% comprised of 26 different other point mutations.

Table 2 presents common adverse reactions that occurred in at least 5% of TEGSEDI-treated patients and that occurred at least 5% more frequently or two times more frequently than on placebo.

The most common adverse reactions that occurred in at least 20% of TEGSEDI-treated patients and more frequently than on placebo were injection site reactions, nausea, headache, fatigue, thrombocytopenia, and fever. Serious adverse reactions were more frequent in TEGSEDI-treated patients (32%) than in patients on placebo (21%). The most common adverse reactions leading to discontinuation were thrombocytopenia and cachexia.
Patients will receive the Houston Methodist Hospital orthopedic surgeon's standard of care pre-operative antibiotic regimen for primary total shoulder arthroplasty patients. This includes IV abx (typically ancef or cefepime and vancomycin) will be started in the pre-operative period approximately 1 hour prior to incision (vancomycin dose weight-based at approximately 15mg/kg \[6,7\] generally 1000-1750mg in 500mL NS).
An ophthalmic composition is described for the treatment of dry eye syndrome in a human or mammal. The composition comprises an aqueous solution including an effective amount of silk protein. The aqueous solution comprises from about 0.01% by weight to about 30% by weight of the silk protein. In one embodiment, the silk protein may be fibroin. A method of treating an eye having an ocular surface is also described. The method comprises providing an ophthalmic composition comprising an aqueous solution including an effective amount of silk protein, and administering the ophthalmic composition topically to the ocular surface.
The invention relates to an ointment for treating hemorrhoids and a preparation method thereof, belonging to the technical field of Chinese patent drugs. The ointment for treating hemorrhoids comprises the following components according to parts by weight: 5-7g of cinnabar, 6-8g of amber, 5-8g of keel, 6-9g of borneol, 6-8g of Sanxian, 9-12g of liquid powder and 25-45g of camellia oil. The ointment for treating hemorrhoids is used for treating various anal diseases, such as internal hemorrhoids, external hemorrhoids, mixed hemorrhoid, anal fissure, anal cyst and the like, quickly becomes effective and has remarkable curative effects. The effective rate can reach 100%, and the cure rate can reach above 97%. Patients do not suffer from surgical pains. The ointment for treating hemorrhoids has no toxic or side effect, does not affect working and studying and has low cost and treatment cost.
Patients will be placed in the lateral position,The high-frequency linear probe will be placed on the lateral abdomen, slightly cephalic to the iliac crest. Once the QL muscle will be observed, the probe will be tilted slightly to the caudal direction, to show the largest slice of the QL muscle, to confirm its posterior aspect. A 22-G block needle (Stimuplex D, Braun, Hongo, Bunkyo-ku, and Tokyo) will be inserted in-plane, \~1 cm ventral to the probe. The needle tip will be advanced until it penetrates the posterior fascia of the QL muscle. A small amount of saline will be injected to confirm the correct position of the tip, between the QL muscle and the erector spinae and latissimus dorsi muscles (Posterior or QL block type 2), then a bolus of 0.5 ml/Kg bupivacaine 0.25% will be injected.
BACKGROUND: Many patients with transverse myelitis suffer from sensory loss below the spinal level of the lesion. This is commonly associated with chronic neuropathic pain. However, the presence of somatic pain below a complete thoracic sensory level after transverse myelitis is exceptionally rare, and it is unclear if surgical decompression is an effective form of treatment for these patients.
CASE PRESENTATION: In this report, we describe a 22-year-old Caucasian female who suffered from chronic lumbar back pain despite a complete thoracic sensory level secondary to prior transverse myelitis. Imaging demonstrated multilevel central stenosis below the sensory level, and her pain improved after surgical decompression. To our knowledge, this is the first reported case of symptomatic lumbar stenosis below a sensory level after transverse myelitis successfully treated with surgical decompression.
CONCLUSION: This is the first reported case of a patient with symptomatic lumbar stenosis after transverse myelitis whose lower back pain and quality of life improved following surgical decompression and fusion. This case provides evidence that typical lumbago is possible in patients with sensory loss from transverse myelitis, and standard lumbar decompression may provide benefit for these patients.
In a 104-week carcinogenicity study in rats, there was an increased incidence of benign and malignant adrenal pheochromocytomas in both males and females at oral doses of 0.04, 0.13, and 0.39 mcg/kg/day (less than the maximum recommended human oral dose of 60 mcg/week based on mcg/m2 body surface area). This increased incidence of pheochromocytomas in rats may be due to altered calcium homeostasis by doxercalciferol. No evidence of genetic toxicity was observed in an in vitro bacterial mutagenicity assay (Ames test) or a mouse lymphoma gene mutation assay. Doxercalciferol caused structural chromatid and chromosome aberrations in an in vitro human lymphocyte clastogenicity assay with metabolic activation. However, doxercalciferol was negative in an in vivo mouse micronucleus clastogenicity assay. 

Doxercalciferol had no effect on male or female fertility in rats at oral doses up to 2.5 mcg/kg/day (approximately 3 times the maximum recommended human oral dose of 60 mcg/week based on mcg/m2 body surface area).
A care system for predicting bed exit and suitable for a frame supporting a patient is provided. The care system includes a boundary-crossing detection system, a location sensing system, and a control circuit. The boundary-crossing detection system is coupled with the frame. The location sensing system is coupled with the frame, and is for obtaining relative position information between the patient and the frame. The control circuit is for data communicating with the boundary-crossing detection system and the location sensing system, and is for accessing care data defining multiple bed-exit behaviors. When one of following situations occurs, the control circuit transmits a warning signal: (1) the control circuit determines that, according to the relative position information and the care data, a current behavior of the patient corresponds to one of the multiple bed-exit behaviors; and (2) the boundary-crossing detection system senses that an object is passing through.
A medicament package comprises a vessel adapted to hold a quantity of a liquid vehicle. The vessel has an opening formed therein. The opening engages a deformable enclosure which receives a medicament container that contains a unit dose of a medicament. The entire medicament package is sterile and is arranged such that by deformation of the enclosure the container may be dislodged from the enclosure into the vessel whereby the medicament may escape from the container and mix with the liquid vehicle. The medicament container is formed with one or more dispensing apertures through which the medicament may exit the container and/or liquid can enter the container. The medicament container may be formed as two or more components, the integrity of the container being maintained by its engagement with the enclosure and that integrity being lost once the container is released from the enclosure.
The invention discloses a dexamethasone acetate slow-release preparation and a preparation method thereof. The dexamethasone acetate slow-release preparation is composed of, by weight, 2-4 parts of dexamethasone acetate, 40-55 parts of matrix-type slow-release material, 0.5-1 part of lubricant, 30-40 parts of filling agent and 1-2 parts of surfactant, the matrix-type slow-release material is cellulose acetate and sodium alginate, and consumption ratio of cellulose acetate and sodium alginate is 1-2:3. The dexamethasone acetate slow-release preparation is formed by material preparing, pelleting and tabletting. The dexamethasone acetate slow-release preparation can release drug lastingly and slowly in vivo, and blood-drug concentration is stable and small in fluctuation, so that administration frequency is lowered, and patient compliance is improved. Efficacy is maintained by controlling concentration, of the preparation, in blood, number of drug release peak times is reduced, and visceral organs of a patient are protected to a certain degree. The dexamethasone acetate slow-release preparation is simple in process, high in reproducibility, easy for industrialized production, low in cost and conducive to lowering product price.
In the group with increased tidal volume (IVT), initial plateau pressure (Pplateau) will be monitored and then tidal volume will be increased until Pplateau was 0.04 cm H2O/kg over the initial Pplateau. The PETCO2 will be then adjusted to 4.5 kPa with a flexible corrugated hose placed between the Y-piece of the anaesthesia circle system and the heat and moisture filter (HME) attached to the endotracheal tube.
Cellular senescence is a biological mechanism of aging and age-related diseases. The aim of this study was to examine whether senescence biomarkers are associated with frailty and physical function trajectories in patients undergoing kidney transplantation (KT). We also discussed the relationship between senescence biomarkers and KT function. In this multicenter study, we prospectively assessed plasma levels of senescence biomarkers, frailty as measured by the Physical Frailty Phenotype, and physical function as measured by the Short Physical Performance Battery prior to KT. Frailty, physical function, and KT function were also measured 1 year after KT. Variable associations were assessed using Cox and relaxed least absolute shrinkage and selection operation regression. The cohort consisted of 197 participants (mean age 53 ± 13 years, 61.4% male, and 80.2% White race). Higher pre-KT levels of macrophage-derived chemokine (MDC/CCL22) and growth differentiation factor-15 (GDF-15) were independently associated with less improvement in frailty and/or physical function during the first year after KT. Higher pre-KT levels tumor necrosis factor receptor superfamily member 6 (FAS) and MMP-9 levels were independently associated with lower KT function one year after KT. Pre-KT cellular senescence may contribute to frailty, physical function, and kidney function trajectories during the first year after KT.
Patients receive SVN53-67/M57-KLH peptide vaccine in incomplete Freund's adjuvant SC and sargramostim SC every 2 weeks at weeks 0, 2, 4, and 6 for up to 4 doses and then receive a booster in week 12. Beginning in week 4, patients receive lenalidomide maintenance therapy PO QD in the absence of disease progression or unacceptable toxicity.
PURPOSE:To obtain a sucrase activity inhibitor containing tea polyphenols as active ingredients and free from fear of side effects. CONSTITUTION:The objective inhibitor contains tea polyphenols (e.g. epigallocatechin gallate) as main ingredients and is used singly or by dissolving in a solvent (e.g. water or alcohol), or by mixing with vehicles, diluents, etc., or by adding to foods. When the inhibitor is administered as a medicine, the inhibitor is orally taken at an amount of 0.5-10g/day. When the inhibitor is used by adding to a food, its content is 0.01-2%. The tea polyphenols are obtained by a well-known method, using natural tea leaves as the raw material. Obesity can be suppressed while properly satisfying appetite by inhibiting sucrase activity and it is useful for treating diabetes mellitus.